Info

CoTherix, Inc. is committed to provide pulmonary arterial hypertension (PAH) patients with rapid access to Ventavis® (iloprost) Inhalation Solution, recently approved by the U.S. Food and Drug Administration for the treatment of PAH (WHO Group I) in patients with NYHA class III or IV symptoms. In controlled trials, Ventavis improved a composite endpoint consisting of exercise tolerance, symptoms (NYHA Class), and lack of deterioration. Ventavis has not been adequately studied with concomitant use of other approved therapies for pulmonary arterial hypertension. Ventavis is now available through CoTherix's specialty pharmacy partners to patients in the United States.